Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
4 MedTech Stocks to Counter Mounting US-China Trade Tensions
by Sweta Jaiswal
In the wake of the impact of the U.S.-China trade war on the MedTech space, we have doubled down on some stocks which offer a safe haven to investors.
Here's Why You Should Add Edwards Lifesciences Right Away
by Zacks Equity Research
We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.
Edwards Lifesciences (EW) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Edwards Lifesciences (EW) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Here's Why You Should Steer Clear of AmerisourceBergen Now (Revised)
by Zacks Equity Research
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.
Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q2.
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
by Zacks Equity Research
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) continued focus on research and development and strategic buyouts are likely to drive Q2 results.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) Q2 results are likely to show softer performance owing to declining revenues across core business segments.
What's in Store for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q3 results are likely to be driven by its core Pharmaceutical Distribution business; a competitive industry is a headwind.
Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.
Can Business Services Aid athenahealth's (ATHN) Q2 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) core Business Services unit is likely to drive growth in Q2; the company's focus on cloud-based services is encouraging.
Can Overall Growth Drive Align Technology (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q2.
Here's Why You Should Add Edwards Lifesciences (EW) Now
by Zacks Equity Research
We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.
Bear of the Day: Barrick Gold (ABX)
by Kevin Cook
Growth estimates were falling when gold was rising, thus not surprising to see them slip further
Should iShares Morningstar Mid-Cap Growth ETF (JKH) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JKH
How to Play the New Hawkish Fed
by Kevin Cook
If you understand what stock market players are afraid of, you can ride the market to higher gains this summer.
Why Is Edwards Lifesciences (EW) Up 1.5% Since Its Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.
Why Earnings Season Could Be Great for Edwards Lifesciences (EW)
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Edwards Lifesciences' (EW) THVT Likely to Drive Q1 Earnings
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies in Q1.
Can Steady Overall Growth Drive Align's (ALGN) Q1 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is likely to gain from strength in the Invisalign space as well as Scanner and Service business in Q1.
Here's Why You Should Steer Clear of AmerisourceBergen Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.
Medical Instrument Stocks Head-to-Head: Abiomed vs. STERIS
by Zacks Equity Research
Here we take a look at the fundamentals of Abiomed (ABMD) and STERIS (STE) to determine which stock is a better pick in the Medical Instruments space.